Get the Stockscreener App
4.36
8.02%
-0.38
Neuphoria Therapeutics Inc stock is traded at $4.36, with a volume of 75,264.
It is down -8.02% in the last 24 hours and down -71.91% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$4.74
Open:
$4.74
24h Volume:
75,264
Relative Volume:
0.05
Market Cap:
$11.18M
Revenue:
$15.66M
Net Income/Loss:
$5.83M
P/E Ratio:
-0.1825
EPS:
-23.8939
Net Cash Flow:
$466.20K
1W Performance:
-11.02%
1M Performance:
-71.91%
6M Performance:
-11.30%
1Y Performance:
+0.00%
1-Day Range:
$4.29
$4.80
1-Week Range:
$4.29
$5.00
52-Week Range:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.36 | 11.18M | 15.66M | 5.83M | 466.20K | -23.89 |
|
ARGX
Argen X Se Adr
|
913.71 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
201.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.16 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
355.38 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.81 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Will Neuphoria Therapeutics Inc. stock continue upward momentumJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
How supply chain issues affect Neuphoria Therapeutics Inc. stock2025 Trade Ideas & Fast Gain Swing Alerts - newser.com
How to read the order book for Neuphoria Therapeutics Inc.Weekly Trend Summary & Target Return Focused Picks - newser.com
What indicators show strength in Neuphoria Therapeutics Inc.Portfolio Risk Summary & High Yield Equity Trading Tips - newser.com
What does recent volatility data suggest for Neuphoria Therapeutics Inc.Weekly Trend Recap & AI Driven Price Predictions - newser.com
Is Neuphoria Therapeutics Inc. still worth holding after the dip2025 Buyback Activity & Expert Verified Stock Movement Alerts - newser.com
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Neuphoria Therapeutics Inc. meeting your algorithmic filter criteriaTrend Reversal & Reliable Trade Execution Plans - newser.com
What Wall Street predicts for Neuphoria Therapeutics Inc. stock price2025 Price Momentum & AI Enhanced Trading Signals - newser.com
Can Neuphoria Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Fed Impact & Precise Buy Zone Tips - newser.com
Can Neuphoria Therapeutics Inc. stock maintain operating marginsTrade Signal Summary & Free Real-Time Market Sentiment Alerts - newser.com
Is Neuphoria Therapeutics Inc. stock attractive after correctionJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
Neuphoria Therapeutics may offer & sell common stock of up to $20 million from time to timeSEC filing - MarketScreener
Can Neuphoria Therapeutics Inc. stock hit analyst price targetsAnalyst Downgrade & Real-Time Price Movement Reports - Fundação Cultural do Pará
Will Neuphoria Therapeutics Inc. stock deliver shareholder value2025 Analyst Calls & Accurate Entry and Exit Point Alerts - Fundação Cultural do Pará
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition - MSN
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Neuphoria Therapeutics Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025 - MarketScreener
Is Neuphoria Therapeutics Inc. showing signs of accumulation2025 Earnings Impact & Verified Swing Trading Watchlists - newser.com
Combining price and volume data for Neuphoria Therapeutics Inc.Portfolio Value Report & AI Powered Buy/Sell Recommendations - newser.com
Will Neuphoria Therapeutics Inc. stock attract more institutional investors2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com
What analysts say about Neuphoria Therapeutics Inc stockRSI Overbought/Oversold & Free Smart Trading Classes - earlytimes.in
Neuphoria announces initiation of strategic review - MSN
Neuphoria Files a Preliminary Proxy Statement with Securities and Exchange Commission - MarketScreener
Neuphoria Announces Receipt of Nomination Notice from Lynx1 Master - MarketScreener
Why hedge funds are buying Neuphoria Therapeutics Inc. stockMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com
Neuphoria Shares Climb 4% After Launching Strategic Review to Enhance Shareholder Value - MSN
Neuphoria Therapeutic (NEUP) Explores Strategic Options and Faces Acquisition Interest - GuruFocus
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):